Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439610 | 0.91 | PDE4B (0.46) | PDE4BARKHK | |
| SCHEMBL17447237 | 0.90 | KHK (0.54) | PDE4BKHK | |
| SCHEMBL17439511 | 0.89 | PDE4B (0.59) | PDE4BALOX5APFEN1GRIN2B | |
| SCHEMBL17439506 | 0.89 | KHK (0.49) | PDE4BARKHKGRIN2B | |
| SCHEMBL17439532 | 0.87 | PDE4B (0.56) | PDE4BALOX5APFEN1GRIN2B | |
| SCHEMBL17447158 | 0.87 | PDE4B (0.57) | PDE4BALOX5APFEN1GRIN2B | |
| SCHEMBL17447170 | 0.86 | PDE4B (0.42) | PDE4BKHK | |
| SCHEMBL28478995 | 0.86 | PDE4B (0.56) | PDE4BALOX5APFEN1GRIN2B | |
| SCHEMBL17439537 | 0.86 | PDE4B (0.56) | PDE4BALOX5APFEN1GRIN2B | |
| SCHEMBL17439558 | 0.86 | PDE4B (0.56) | PDE4BALOX5APFEN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-9546158-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016008590-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065603-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885AR 3360/4885ALOX5AP 1305/4885 |
| US-20160016938-A1 | Novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885AR 3360/4885ALOX5AP 1305/4885 |
| US-10391099-B2 | Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885AR 4019/4885ALOX5AP 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.